In the present paper, we aimed to investigate whether CSF Cortisol and DHEAS were associated with (1) cognitive and functional performance at baseline; (2) with amyloid pathology (as assessed by CSF Aβ levels), neuronal injury (as assessed by CSF tau), and tau hyperphosphorylation (as assessed by CSF phosphorylated tau or p-tau); (3) regional brain volumetry; and (4) with clinical disease progression at 18 then at 36 months from baseline. Here, MAPT is linked to amyloidosis.